Skip to Content

Incyte Corp INCY Stock Quote

| Rating as of


Market Open

| Currency in USD

  • Last Close 58.10
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Mid Growth
  • Day Range 57.90  –  58.21
  • Year Range 57.90  –  86.08
  • Market Cap 13.0419 Bil
  • Volume / Avg 49,954.0 /  1.6 Mil
  • Price / Sales 3.72
  • Price / Book 2.74
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis INCY

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Incyte's Established Jakafi Market and Launching Dermatology Drug Opzelura Support Narrow Moat

Karen Andersen Sector Strategist

Business Strategy and Outlook

| Karen Andersen |

Incyte has build a solid foundation over the past decade with hematology drug Jakafi, and the approval of the same active ingredient as oral dermatology drug Opzelura is expanding the firm's focus to new therapeutic areas. We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the firm can grow through Jakafi's patent expiration in 2028.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics INCY

Company Profile INCY

Business Description

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

1801 Augustine Cut-Off
Wilmington, DE, 19803
Industry Biotechnology
Employees 2,324

Related Articles INCY

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of INCY’s competitive advantage.

Incyte Corp


Merck & Co Inc


Pfizer Inc


Roche Holding AG

+$0.08 (0.13%) −$1.18 (1.10%) −$0.19 (0.57%) −$2.25 (0.90%)
Market Cap
13.04 Bil266.97 Bil183.52 Bil198.66 Bil
Biotechnology Drug Manufacturers - General Drug Manufacturers - General Drug Manufacturers - General

* Trading data in this section is delayed by at least 15 minutes.

FAQs for Incyte Corp Stock

No. INCY does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

INCY’s market cap is 13.04 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

INCY’s stock style is Mid Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

INCY’s price/sales is 3.72.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

INCY’s price/forward earnings is 35.86.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

INCY’s price/book is 2.74.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See INCY’s valuation ratios compared to the Market Index.

INCY’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare INCY’s historical performance against its industry peers and the overall market.